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OBJECTIVES: In the phase 3 CARE-MS II study (NCT00548405), alemtuzumab dem-
onstrated a reduction in annualized relapse rate (49%) and sustained accumulation 
of disability (42%) versus subcutaneous interferon beta-1a 44 μ g (both P< 0.01). This 
analysis assessed the budget impact (BI) of adding alemtuzumab to a formulary 
containing approved disease-modifying therapies (DMTs) for multiple sclerosis (MS) 
in a hypothetical 100,000-member US health plan. METHODS: Alemtuzumab was 
administered as 2 annual treatment courses to patients with relapsing-remitting 
MS inadequately responding to prior therapy, with as-needed retreatment in an 
extension (NCT00930553). A 5-year BI analysis from a US payer perspective was 
developed with US-approved DMTs included as comparators. The model accounted 
for the effect of DMTs on relapses, but not disability. Key cost inputs included drug 
acquisition, drug administration and monitoring, adverse events (AEs), and cost 
of relapse. Percentage of patients taking alemtuzumab was projected to increase 
gradually from 1.6% in its first year of use to 7.5% by Year 5. RESULTS: Relapse costs 
were reduced beginning the first year of alemtuzumab formulary inclusion, resulting 
in annual relapse cost savings of $25,045 by Year 5. Total costs attributable to DMT 
acquisition, AEs, and monitoring increased with the introduction of alemtuzumab 
($188,516 by Year 5). Total budget impact peaked in Year 4 (plan member per month 
[PMPM] cost= $0.17) and decreased by Year 5 (PMPM= $0.14). This downward trend is 
attributable to decreased drug acquisition and administration costs due to the dura-
bility of alemtuzumab’s effect and increased relapse cost savings. CONCLUSIONS: 
Reduction in relapses, the unique dosing schedule, and durable efficacy for most 
patients in the absence of retreatment, provide significant cost offsets to alemtu-
zumab formulary inclusion compared to formularies not including alemtuzumab. 
The model provides conservative estimates by excluding disability costs, which are 
a major contributor to the cost of caring for MS patients.
PND18
buDgeT ImPAcT of ADDINg PegINTeRfeRoN beTA-1A To THe foRmulARy 
foR THe TReATmeNT of RelAPsINg foRms of mulTIPle scleRosIs
Mauskopf JA1, Graham J2, Fay-Azhar M3, Kinter E3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI-Health Solutions, Research Triangle 
Park, NC, USA, 3Biogen Idec, Weston, MA, USA
OBJECTIVES: To estimate the budget impact of adding peginterferon beta-1a, a new 
interferon requiring injections only every two weeks for the treatment of relapsing 
forms of multiple sclerosis (MS), to a managed care formulary in the US. METHODS: 
An Excel model was developed to compare the drug-related costs of the current mix 
of treatments with the costs of an estimated treatment mix including peginter-
feron beta-1a for a managed care organization (MCO) with 1,000,000 covered lives. 
The number of people with relapsing forms of MS was estimated using published 
prevalence data. Treatment share of peginterferon beta-1a was assumed to increase 
from 3% in 2014 to 7% in 2018 taken proportionately by treatment shares from the 
other interferons indicated for MS. Drug costs included: acquisition costs adjusted 
by patient payments and dispensing fees as well as administration, monitoring, 
and adverse event costs. Annual relapse treatment costs were estimated using the 
relative risk reduction of a relapse for each DMT derived using a mixed-treatment 
comparison analysis A one-way sensitivity analysis was performed. RESULTS: The 
resonance imaging and clinical outcomes. Despite challenges in comparing out-
comes across studies, exploratory analyses of treatment effects can be compared 
informally using relative reductions in a specific endpoint. The number needed to 
treat (NNT) to prevent an event is an important outcome to consider for any com-
parisons within the field of MS. METHODS: NNTs were derived using data from 
studies with teriflunomide 14 mg (TEMSO, NCT00134563; TOWER, NCT00751881) or 
DMF (DEFINE, NCT00420212; CONFIRM, NCT00451451) based on the inverse of abso-
lute differences between treatment and placebo groups. RESULTS: Teriflunomide 
studies included patients with progressive disease; patients in DEFINE had slightly 
lower baseline Expanded Disability Status Scale scores. Teriflunomide and DMF 
significantly reduced risk of relapse (all studies). NNTs to prevent 1 relapse were 
similar across all studies (5.9 [TEMSO], 5.6 [TOWER], 5.3 [DEFINE], 5.6 [CONFIRM]). 
Risk of disability progression sustained for 12 weeks was significantly reduced in 
TEMSO, TOWER, and DEFINE but not CONFIRM. Corresponding NNTs to prevent 
disability progression were 13.8, 17.4, 10.8, and 30.2. Risk of relapse leading to hos-
pitalization was significantly reduced in TEMSO and TOWER but not in DEFINE and 
CONFIRM. Corresponding NNTs were lower in TEMSO (12.5) and TOWER (20) than 
in DEFINE (50) and CONFIRM (50). Safety data and corticosteroid use will be pre-
sented. CONCLUSIONS: Using the NNT approach, we demonstrate a comparable 
effect size for teriflunomide and DMF on relapses. NNTs to prevent disability pro-
gression with teriflunomide showed a consistent significant reduction in risk vs 
placebo in both TEMSO and TOWER. For DMF, comparable NNTs were observed only 
in DEFINE, and not in CONFIRM. Reduction of risk for relapse leading to hospitaliza-
tion was significant only for teriflunomide.
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OBJECTIVES: In Brazil, there are three first line interferonβ for relapsing remit-
ting multiple sclerosis (RRMS): Interferonβ 1a (Rebif® and Avonex®) and 1b 
(Betaferon®). Our aim is to produce a systematic review with meta-analysis 
to compare those Interferon’s-β efficacies in RRMS. METHODS: We searched 
MEDLINE, CENTRAL and others database to identify randomized controlled trials 
evaluating Interferons-β in RRMS. Clinical outcomes evaluated were reduction of 
relapse risk at 12, 24 months, and reduction of disability progression measured 
by the Expanded Disability Status Scale. Aggregated data was evaluated using 
a series of pairwise fixed-effects meta-analyses. RESULTS: From 465 articles 
found, 9 fit the inclusion criteria (5 placebo-controlled and 4 head-to-head tri-
als). The analysis showed that Rebif® reduces relapses at 12 months (RR= 0,85; 
95%CI= 0.77-0.93; P= 0.0005), 24 months (RR= 0.85; 95%CI= 0.77-0.92; P= 0.0002) and 
disability progression at 24 months (RR= 0.76; 95%CI= 0.61-0.95; P= 0.02) compared 
to placebo. Betaferon® reduces relapses at 24 months (RR= 0.89; 95%CI= 0.81-0.99; 
P= 0.03) but does not differ significantly from placebo in relapses over 12 months 
or disability progression. Avonex® does not differ significantly from placebo at 
any endpoint. From the 4 head-to-head trials: two compared Betaferon® and 
Avonex® showing Betaferon® superior in reducing disability progression at 24 
months (RR= 0.76; 95%CI= 0.59-0.9; P= 0.03); one comparing Rebif® to Avonex® 
showed superiority of Rebif® in decreasing relapses at 24 months and time to 
first relapse; one showed no differences in annual relapses between Betaferon® 
and Rebif®. CONCLUSIONS: Betaferon® did not reduce relapse risk in 12 months 
and disability progression. Avonex® did not demonstrate significant reduction 
in relapse risk reduction at 12 and 24 months as well as reduction of disability 
progression when compared to placebo. Among the approved first-line treatment 
interferon-β only Rebif® demonstrate statistically significant lower risk of relapse 
in 12 and 24 months as well as reduction in disability progression.
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OBJECTIVES: Parkinson’s disease (PD) is a neurodegenerative disorder causing pro-
gressive motor impairment and disability. The effects of PD are measure throughout 
the Unified Parkinson’s Disease Rating Scale (UPDRS). PD treatments include drugs 
that increase the functional ability of the underactive dopaminergic system or that 
reduce the excessive influence of excitatory cholinergic neurons. The purpose of this 
study was to conduct an indirect comparison of the efficacy of different alternatives 
of early treatment for Parkinson’s disease regarding the UPDRS. METHODS: We 
realized a systematic literature review in eigth data base with keys word: Parkinson 
disease, early treatment, levodopa, pramipexole, rasagiline, selegiline and placebo. 
The inclusion criteria were patients with parkinson’s disease in Hoehn and Yahr I, 
2 or 3, UPDRS scale, lenguaje spanish and english, since January 1994 to May 2014. 
Results of all trials were analyzed simultaneously with a Bayesian Mixed Treatment 
Comparison (MTC) to obtain the relative efficacy into the treatments. RESULTS: 
There were 1080 clinical trials (CT), only five meeting the inclusion criteria: levodopa 
(1CT), pramipexole (1 CT), rasagiline (2CT) and selegiline (1CT), using a random 
model levodopa showed the best punctuation in UPDRS (probability= 0.61) when all 
the treatments were compared. Also, it showed a mean difference of 7 relative to 
placebo, CrI (0.14-14); 2.2 relative to pramipexole CrI (-7.5- 12); 3.5 relative to rasagil-
ine, CrI (-4.8-12) and 1.6 relative to selegiline, CrI (-8.3-12). CONCLUSIONS: Findings 
of this study indicate that Levodopa provides a greater disability and impairment 
reduction in patients with Parkinson disease (measured by UPDRS) patients than 
pramipexole, rasagiline and selegiline as first treatment option to early parkinson’s 
disease in monotherapy.
